Search

Your search keyword '"Chouaïd C"' showing total 747 results

Search Constraints

Start Over You searched for: Author "Chouaïd C" Remove constraint Author: "Chouaïd C"
747 results on '"Chouaïd C"'

Search Results

1. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review

4. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

7. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

11. Explore ALK : Alectinib chez les patients atteints de cancer du poumon non à petites cellules métastatique ALK+: une analyse nationale en vie réelle (GFPC 03-2019)

24. Recommandations de bonne pratique : surveillance médico-professionnelle des travailleurs exposés ou ayant été exposés à des agents cancérogènes pulmonaires

25. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

26. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC – IFCT 02-01

28. 76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis

36. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

41. Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

42. 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study

43. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Catalog

Books, media, physical & digital resources